Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2002

01-12-2002 | Original Article

Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial

Authors: Theodore F. Logan, Fayega Jadali, Merrill J. Egorin, Mark Mintun, Donald Sashin, William E. Gooding, Yong Choi, Harry Bishop, Donald L. Trump, Diane Gardner, John Kirkwood, Daniel Vlock, Candace Johnson

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2002

Login to get access
Metadata
Title
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial
Authors
Theodore F. Logan
Fayega Jadali
Merrill J. Egorin
Mark Mintun
Donald Sashin
William E. Gooding
Yong Choi
Harry Bishop
Donald L. Trump
Diane Gardner
John Kirkwood
Daniel Vlock
Candace Johnson
Publication date
01-12-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0517-4

Other articles of this Issue 6/2002

Cancer Chemotherapy and Pharmacology 6/2002 Go to the issue

Original Article

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925

Original Article

Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat

Original Article

Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice

Short Communication

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule

Original Article

Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518

Original Article

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits